Last update 25 May 2025

Hearing loss gene therapy(Baylor College of Medicine)

Overview

Basic Info

Drug Type
Gene therapy
Synonyms
CGF 166, CGF-166, CGF166
Target
ATOH1
Action
stimulants
Mechanism
ATOH1 stimulants(Protein atonal homolog 1 stimulants), Gene transference(Gene transference)
Therapeutic Areas
Nervous System DiseasesOtorhinolaryngologic DiseasesOther Diseases
Active Indication-
Inactive Indication
Hearing Loss, BilateralHearing Loss, Unilateral
Originator Organization
Baylor College of MedicineBaylor College of Medicine
Active Organization-
Inactive Organization
Novartis Pharmaceuticals Corp.Novartis Pharmaceuticals Corp.
License Organization-
Drug Highest PhasePendingPhase 1/2
First Approval Date-
Regulation-
Login to view timeline

Related

1
Clinical Trials associated with Hearing loss gene therapy(Baylor College of Medicine)
NCT02132130
/ CompletedPhase 1/2
A Three-part, Multicenter, Open Label, Single Dose Study to Assess the Safety, Tolerability, and Efficacy of Intra Labyrinthine (IL) CGF166 in Patients With Severe-to-profound Hearing Loss
100 Clinical Results associated with Hearing loss gene therapy(Baylor College of Medicine)
Login to view more data
100 Translational Medicine associated with Hearing loss gene therapy(Baylor College of Medicine)
Login to view more data
100 Patents (Medical) associated with Hearing loss gene therapy(Baylor College of Medicine)
Login to view more data
100 Deals associated with Hearing loss gene therapy(Baylor College of Medicine)
Login to view more data

R&D Status

10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Hearing Loss, BilateralPhase 2
United States
Novartis Pharmaceuticals Corp.Novartis Pharmaceuticals Corp.
23 Jun 2014
Hearing Loss, UnilateralPhase 2
United States
Novartis Pharmaceuticals Corp.Novartis Pharmaceuticals Corp.
23 Jun 2014
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
NCT02132130 (CTgov)
Phase 1/2
Hearing Loss | Hearing Loss, Unilateral | Hearing Loss, Bilateral
22
(CGF166 Dose 20 μL)
jtkfioewmd = ngjoozfvdd vwqpxzirnl (ufzsigdmmo, wavsskmnva - jlxkrsmhac)
View more
-
30 Mar 2021
(CGF166 Dose 30 μLEdit Single Dose Volume #2)
jtkfioewmd = sgvyjefwul vwqpxzirnl (ufzsigdmmo, mjlokefqrz - nxehmiycew)
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
login
or
view full example data
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
login
or
view full example data
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
login
or
view full example data
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
login
or
view full example data
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
login
or
view full example data
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
login
or
view full example data
Understand key drug designations in just a few clicks with Synapse.
AI Agents Built for Biopharma Breakthroughs
Accelerate discovery. Empower decisions. Transform outcomes.
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free